-$0.30 Earnings Per Share Expected for MorphoSys AG Unsponsored ADR (MOR) This Quarter

Brokerages expect MorphoSys AG Unsponsored ADR (NYSE:MOR) to report earnings of ($0.30) per share for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for MorphoSys’ earnings. The lowest EPS estimate is ($0.31) and the highest is ($0.28). MorphoSys posted earnings of ($0.15) per share in the same quarter last year, which would indicate a negative year over year growth rate of 100%. The firm is expected to issue its next quarterly earnings results on Tuesday, March 12th.

On average, analysts expect that MorphoSys will report full year earnings of ($0.45) per share for the current fiscal year, with EPS estimates ranging from ($0.51) to ($0.41). For the next year, analysts expect that the company will report earnings of ($0.87) per share, with EPS estimates ranging from ($0.93) to ($0.81). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that cover MorphoSys.

MorphoSys (NYSE:MOR) last issued its earnings results on Monday, November 5th. The company reported $0.28 earnings per share (EPS) for the quarter. The firm had revenue of $63.98 million during the quarter.

Separately, Leerink Swann reissued an “outperform” rating on shares of MorphoSys in a report on Friday, January 11th.

MorphoSys stock traded down $0.36 during trading hours on Tuesday, hitting $28.75. The stock had a trading volume of 2,818 shares, compared to its average volume of 21,385. MorphoSys has a 12-month low of $21.75 and a 12-month high of $35.90.

MorphoSys Company Profile

MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnership with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 drugs for the treatment of cancer, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.

Featured Story: How to calculate compound interest

Get a free copy of the Zacks research report on MorphoSys (MOR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply